PMID- 29886587
OWN - NLM
STAT- MEDLINE
DCOM- 20180709
LR  - 20181202
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 47
IP  - 6
DP  - 2018 Jun 8
TI  - [Histologic subtyping of poorly-differentiated solid lung cancer with molecular 
      testing for epidermal growth factor receptor mutation and ALK gene rearrangement: 
      an analyses of 167 cases].
PG  - 432-437
LID - 10.3760/cma.j.issn.0529-5807.2018.06.009 [doi]
AB  - Objective: To study the histological subtyping of poorly differentiated solid 
      lung cancer by using immunohistochemistry and mucin staining along with analysis 
      of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma 
      kinase (ALK) gene rearrangement. Methods: Among 827 cases of non-small cell lung 
      cancer at Beijing Hospital from April 2014 to April 2017, 167 cases of solid 
      poorly differentiated lung cancer were identified and histopathologically 
      subtyped by mucin staining (D-PAS) and immunohistochemistry using 10 antibodies 
      (CK7, vimentin, Ki-67, CK5/6, p40, TTF1, Napsin A, CD56, chromogranin A, and 
      synaptophysin). Paraffin embedded tumor samples were subjected to mutation 
      analysis of exons 18, 19, 20 and 21 of the EGFR gene by amplification refractory 
      mutation system (ARMS) method. Immunohistochemistry (Ventana D5F3) for ALK gene 
      rearrangement was performed followed by ALK fluorescence in situ hybridization 
      (FISH) verification. Results: There were 79 females and 88 males in the study 
      cohort. The patient's age ranged from 35 to 77 years (mean 62 years). Cases with 
      solid growth pattern (at least >10%) and without typical histological features of 
      adenocarcinoma, squamous cell carcinoma or neuroendocrine carcinoma were further 
      divided based on immunohistochemistry and mucin stain into 64 cases(38.32%)of 
      adenocarcinoma, 34 cases(20.35%) squamous cell carcinoma, 21 cases(12.57%)large 
      cell neuroendocrine carcinoma, 5 cases(2.99%)combined large cell neuroendocrine 
      carcinoma, 2 cases(1.20%)adenosquamous carcinoma and 41 cases(24.55%)large cell 
      carcinoma. The Ki-67 positive rate ranged from 5% to 65%. Mutations of EGFR were 
      detected in 5 cases (2.99%, 5/167) of adenocarcinoma(19del in 3 cases and L858R 
      in 2 cases). Two cases(1.20%, 2/167) with ALK-rearranged were identified by 
      immunohistochemistry (Ventana D5F3) and confirmed by ALK FISH. Conclusions: 
      Poorly differentiated solid lung cancer without distinct morphological features 
      can be further histologically subtyped by mucin staining and 
      immunohistochemistry. Molecular testing should be performed for accurate 
      molecular target therapy to improve the prognosis.
FAU - Fang, F
AU  - Fang F
AD  - Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
FAU - Wang, Y X
AU  - Wang YX
FAU - Hu, S T
AU  - Hu ST
FAU - Yang, L
AU  - Yang L
FAU - Di, J
AU  - Di J
FAU - Liu, D G
AU  - Liu DG
FAU - Lyu, N
AU  - Lyu N
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/genetics/pathology
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Adenosquamous/genetics/pathology
MH  - Carcinoma, Neuroendocrine/genetics/pathology
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/*pathology
MH  - Carcinoma, Squamous Cell/genetics/pathology
MH  - DNA Mutational Analysis
MH  - ErbB Receptors
MH  - Exons
MH  - Female
MH  - *Gene Rearrangement
MH  - Genes, erbB-1/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Prognosis
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Small Cell Lung Carcinoma/genetics/pathology
OTO - NOTNLM
OT  - Carcinoma, non-small-cell lung
OT  - DNA mutational analysis
OT  - Gene rearrangement
OT  - Immunohistochemistry
OT  - Receptor, epidermal growth factor
OT  - Solid lung cancer
EDAT- 2018/06/12 06:00
MHDA- 2018/07/10 06:00
CRDT- 2018/06/11 06:00
PHST- 2018/06/11 06:00 [entrez]
PHST- 2018/06/12 06:00 [pubmed]
PHST- 2018/07/10 06:00 [medline]
AID - 10.3760/cma.j.issn.0529-5807.2018.06.009 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2018 Jun 8;47(6):432-437. doi: 
      10.3760/cma.j.issn.0529-5807.2018.06.009.